Alnylam Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1,657	966.43	812.69	866.39	819.98
Short-Term Investments	1,251	1,728	1,627	1,326	1,616
Cash & Short-Term Investments	2,908	2,695	2,439	2,192	2,436
Cash Growth	7.94%	10.46%	11.27%	-9.98%	29.94%
Accounts Receivable	777.57	405.31	327.79	237.96	198.57
Receivables	777.57	405.31	327.79	237.96	198.57
Inventory	82.72	78.51	89.15	128.96	86.36
Prepaid Expenses	281.89	116.96	126.38	132.92	88.08
Total Current Assets	4,051	3,295	2,983	2,692	2,809
Property, Plant & Equipment	708.06	693.93	725.79	738.63	733.63
Long-Term Deferred Tax Assets	125.98	116.86	10.1	-	-
Other Long-Term Assets	81.63	133.9	111.29	115.48	101.1
Total Assets	4,966	4,240	3,830	3,546	3,643
Accounts Payable	115.72	88.42	55.52	98.09	73.43
Accrued Expenses	821.34	701.38	654.73	513.78	372.33
Current Portion of Long-Term Debt	220.07	113.02	54.99	40.29	37.08
Current Portion of Leases	45.52	41.89	41.51	41.97	40.55
Current Unearned Revenue	4.85	55.48	102.75	42.11	149.48
Other Current Liabilities	258.86	186.09	58.28	31.68	22.84
Total Current Liabilities	1,466	1,186	967.79	767.92	695.71
Long-Term Debt	2,478	2,359	2,343	2,269	1,827
Long-Term Leases	225.09	229.54	243.1	261.34	281.35
Long-Term Unearned Revenue	-	-	188.18	193.79	152.36
Other Long-Term Liabilities	7.59	398.11	308.44	212.58	98.96
Total Liabilities	4,177	4,173	4,051	3,705	3,055
Common Stock	1.32	1.29	1.26	1.24	1.2
Additional Paid-In Capital	7,510	7,388	6,811	6,455	6,058
Retained Earnings	-6,703	-7,288	-7,010	-6,569	-5,438
Comprehensive Income & Other	-20.1	-34.52	-23.38	-44.65	-33.26
Shareholders' Equity	789.18	67.09	-220.64	-158.22	588.2
Total Liabilities & Equity	4,966	4,240	3,830	3,546	3,643
Total Debt	2,969	2,743	2,683	2,613	2,186
Net Cash (Debt)	-60.31	-48.92	-243.24	-420.15	249.87
Net Cash Growth	-	-	-	-	-11.29%
Net Cash Per Share	-0.45	-0.38	-1.95	-3.45	2.11
Filing Date Shares Outstanding	132.62	129.46	125.95	124.13	120.21
Total Common Shares Outstanding	132.38	129.29	125.79	123.93	120.18
Working Capital	2,584	2,109	2,015	1,924	2,113
Book Value Per Share	5.96	0.52	-1.75	-1.28	4.89
Tangible Book Value	789.18	67.09	-220.64	-158.22	588.2
Tangible Book Value Per Share	5.96	0.52	-1.75	-1.28	4.89
Land	9.08	9.08	9.08	9.08	9.08
Buildings	297.62	294.51	271.65	269.32	262.64
Machinery	247.12	225.2	202.89	173.1	137.86
Construction In Progress	40.95	7.67	30.1	14.6	80.75
Leasehold Improvements	241.08	236.69	235.41	230.85	152.05

Updated Feb 12, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q